A nationwide 104 weeks real‐world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head‐and‐neck dermatitis
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
A nationwide 104 weeks real‐world study of dupilumab in adults with atopic dermatitis : Ineffectiveness in head‐and‐neck dermatitis. / Vittrup, Ida; Krogh, Niels Steen; Larsen, Henrik Hedegaard Pliess; Elberling, Jesper; Skov, Lone; Ibler, Kristina Sophie; Jemec, Gregor B. E.; Mortz, Charlotte G.; Bach, Rasmus Overgaard; Bindslev‐jensen, Carsten; Dalager, Maiken Glud; Egeberg, Alexander; Agner, Tove; Deleuran, Mette; Vestergaard, Christian; Thyssen, Jacob Pontoppidan.
In: Journal of the European Academy of Dermatology and Venereology, Vol. 37, No. 5, 2023, p. 1046-1055.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A nationwide 104 weeks real‐world study of dupilumab in adults with atopic dermatitis
T2 - Ineffectiveness in head‐and‐neck dermatitis
AU - Vittrup, Ida
AU - Krogh, Niels Steen
AU - Larsen, Henrik Hedegaard Pliess
AU - Elberling, Jesper
AU - Skov, Lone
AU - Ibler, Kristina Sophie
AU - Jemec, Gregor B. E.
AU - Mortz, Charlotte G.
AU - Bach, Rasmus Overgaard
AU - Bindslev‐jensen, Carsten
AU - Dalager, Maiken Glud
AU - Egeberg, Alexander
AU - Agner, Tove
AU - Deleuran, Mette
AU - Vestergaard, Christian
AU - Thyssen, Jacob Pontoppidan
PY - 2023
Y1 - 2023
N2 - BackgroundEvaluation of effectiveness and safety of new systemic treatments for atopic dermatitis (AD) after approval is important. There are few published data exceeding 52-week therapy with dupilumab.ObjectivesTo examine the safety, effectiveness and drug survival of dupilumab in a Danish nationwide cohort with moderate-to-severe AD up to 104 weeks exposure.MethodsWe included 347 adult patients with AD who were treated with dupilumab and registered in the SCRATCH registry during 2017–2022.ResultsAt all visits, we observed improvement in AD severity measured by Eczema Area and Severity Index (EASI) [median (IQR)]. EASI score at baseline was 18.0 (10.6–25.2), at week 4: 6.5 (3.5–11.6), at week 16: 3.7 (1.2–6.2), at week 52: 2.0 (0.8–3.6), at week 104: 1.7 (0.8–3.8). While drug survival was high (week 52: 90%; week 104: 86%), AD in the head-and-neck area remained present in most patients at high levels; proportion with head-and-neck AD at baseline was 76% and 68% at week 104. 35% of patients reported any AE. Conjunctivitis was the most frequent (25% of all patients) and median time to first registration of conjunctivitis was 201 days.ConclusionsWhile 2-year drug survival was 86%, dupilumab was unable to effectively treat AD in the head-and-neck area, and conjunctivitis was found in 25% of patients.
AB - BackgroundEvaluation of effectiveness and safety of new systemic treatments for atopic dermatitis (AD) after approval is important. There are few published data exceeding 52-week therapy with dupilumab.ObjectivesTo examine the safety, effectiveness and drug survival of dupilumab in a Danish nationwide cohort with moderate-to-severe AD up to 104 weeks exposure.MethodsWe included 347 adult patients with AD who were treated with dupilumab and registered in the SCRATCH registry during 2017–2022.ResultsAt all visits, we observed improvement in AD severity measured by Eczema Area and Severity Index (EASI) [median (IQR)]. EASI score at baseline was 18.0 (10.6–25.2), at week 4: 6.5 (3.5–11.6), at week 16: 3.7 (1.2–6.2), at week 52: 2.0 (0.8–3.6), at week 104: 1.7 (0.8–3.8). While drug survival was high (week 52: 90%; week 104: 86%), AD in the head-and-neck area remained present in most patients at high levels; proportion with head-and-neck AD at baseline was 76% and 68% at week 104. 35% of patients reported any AE. Conjunctivitis was the most frequent (25% of all patients) and median time to first registration of conjunctivitis was 201 days.ConclusionsWhile 2-year drug survival was 86%, dupilumab was unable to effectively treat AD in the head-and-neck area, and conjunctivitis was found in 25% of patients.
U2 - 10.1111/jdv.18849
DO - 10.1111/jdv.18849
M3 - Journal article
C2 - 36606551
VL - 37
SP - 1046
EP - 1055
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
SN - 0929-0168
IS - 5
ER -
ID: 337728559